NFSG
FATE icon

Newbridge Financial Services Group’s Fate Therapeutics FATE Stock Holding History

Newbridge Financial Services Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16
Closed -$34 – 1221
2023
Q3 		$34 Hold
16
– – ﹤0.01% 1267
2023
Q2 		$76 Hold
16
– – ﹤0.01% 1308
2023
Q1 		$91 Hold
16
– – ﹤0.01% 1366
2022
Q4 		$161 Hold
16
– – ﹤0.01% 1392
2022
Q3 		$0 Hold
16
– – ﹤0.01% 1410
2022
Q2 		$0 Hold
16
– – ﹤0.01% 1402
2022
Q1 		$1K Hold
16
– – ﹤0.01% 1372
2021
Q4 		$1K Hold
16
– – ﹤0.01% 1319
2021
Q3 		$1K Hold
16
– – ﹤0.01% 1251
2021
Q2 		$1K Hold
16
– – ﹤0.01% 1349
2021
Q1 		$1K Buy
+16
New +$1.53K ﹤0.01% 1266

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Newbridge Financial Services Group's FATE Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 16 shares — an estimated $34 sold.

Newbridge Financial Services Group first reported a position in FATE in Q1 2021 and held it in 11 quarters. The position peaked at $1K in Q1 2022. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 16 Fate Therapeutics shares in Q4 2023, an estimated $34.
  • Newbridge Financial Services Group first reported a position in Fate Therapeutics in Q1 2021 and held it in 11 quarters.
  • Newbridge Financial Services Group's Fate Therapeutics position peaked at $1K in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.